The delivery of antisense therapeutics.

Abstract

Antisense oligonucleotides, ribozymes and DNAzymes have emerged as novel, highly selective inhibitors or modulators of gene expression. Indeed, their use in the treatment of diseases arising from genetic abnormalities has become a real possibility over the past few years. The first antisense drug molecule is now available for clinical use in Europe and USA. However, their successful application in the clinic will require improvements in cellular targeting and intracellular delivery. This review aims to look at recent advances in the in vitro and in vivo delivery of antisense oligodeoxynucleotides and ribozymes.

0100200'02'04'06'08'10'12'14'16
Citations per Year

1,352 Citations

Semantic Scholar estimates that this publication has 1,352 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Akhtar2000TheDO, title={The delivery of antisense therapeutics.}, author={S Akhtar and M D Hughes and A Khan and M Bibby and M Hussain and Q Nawaz and J Double and P Sayyed}, journal={Advanced drug delivery reviews}, year={2000}, volume={44 1}, pages={3-21} }